CD274 and gastric cancer: The phase III KEYNOTE-062 trial showed that pembrolizumab monotherapy was non-inferior to chemotherapy in terms of OS for untreated advanced GC or gastroesophageal junction (GEJ) cancer patients with PD-L1 CPS ≥ 1, with fewer adverse events.